Colleagues on for Paul Choi's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for Paul Choi at Goldman Sachs asked about strategies to differentiate aficamtan on patient access for commercial and Medicare patients compared to its competitor.
Answer
Andrew Callos, EVP & Chief Commercial Officer, stated the goal is to achieve access parity with the competitor. He emphasized that differentiation will come from the clinical data, a potentially superior REMS, and a patient-centric support program, including co-pay assistance and other services.